IRIS
SIGNORIELLO, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.586
AS - Asia 1.964
NA - Nord America 1.880
SA - Sud America 387
AF - Africa 30
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.852
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 3.338
US - Stati Uniti d'America 1.828
SG - Singapore 680
CN - Cina 430
IE - Irlanda 406
BR - Brasile 333
HK - Hong Kong 310
VN - Vietnam 273
IT - Italia 247
DE - Germania 164
GB - Regno Unito 155
KR - Corea 104
IN - India 52
UA - Ucraina 47
FR - Francia 42
JP - Giappone 34
GR - Grecia 32
FI - Finlandia 30
MX - Messico 29
AR - Argentina 28
PL - Polonia 19
SE - Svezia 19
CA - Canada 17
TR - Turchia 17
AT - Austria 14
NL - Olanda 13
IQ - Iraq 12
ES - Italia 11
BE - Belgio 10
CZ - Repubblica Ceca 10
ID - Indonesia 10
EC - Ecuador 9
BD - Bangladesh 8
HU - Ungheria 7
PK - Pakistan 7
MA - Marocco 6
TN - Tunisia 6
IL - Israele 5
LT - Lituania 5
ZA - Sudafrica 5
CO - Colombia 4
SA - Arabia Saudita 4
AZ - Azerbaigian 3
BO - Bolivia 3
CH - Svizzera 3
EG - Egitto 3
PT - Portogallo 3
PY - Paraguay 3
RS - Serbia 3
AU - Australia 2
BY - Bielorussia 2
CL - Cile 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
JO - Giordania 2
KE - Kenya 2
KG - Kirghizistan 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
PE - Perù 2
UZ - Uzbekistan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
CG - Congo 1
CY - Cipro 1
DK - Danimarca 1
DZ - Algeria 1
IR - Iran 1
IS - Islanda 1
JM - Giamaica 1
KZ - Kazakistan 1
LV - Lettonia 1
MD - Moldavia 1
MY - Malesia 1
NP - Nepal 1
PA - Panama 1
PH - Filippine 1
RO - Romania 1
SN - Senegal 1
TH - Thailandia 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.852
Salva come PNG Salva come JPEG
Città #
Moscow 1.165
Dublin 404
Hong Kong 306
Santa Clara 297
Singapore 288
San Jose 250
Chandler 148
Seoul 103
Ho Chi Minh City 100
Ashburn 91
Hefei 87
Dallas 86
Jacksonville 79
Beijing 68
Hanoi 56
Munich 55
Princeton 53
Roxbury 53
Bremen 46
New York 44
Caserta 42
Naples 42
The Dalles 36
Ann Arbor 32
Bengaluru 32
Los Angeles 31
Cambridge 30
Medford 30
São Paulo 30
Redhill 26
Boardman 18
Da Nang 16
Warsaw 16
Wilmington 16
Milan 15
Aversa 14
Des Moines 14
Nuremberg 13
Rio de Janeiro 13
Haiphong 12
Helsinki 12
Norwalk 12
Brussels 10
Mexico City 10
Turku 10
Falkenstein 9
Atlanta 8
Ninh Bình 8
Belo Horizonte 7
Frankfurt am Main 7
Houston 7
Nanjing 7
Orem 7
Rome 7
San Francisco 7
Tokyo 7
Amsterdam 6
Ankara 6
Boston 6
Redwood City 6
San Mateo 6
Stockholm 6
Thái Bình 6
Tianjin 6
Toronto 6
Vienna 6
Brasília 5
Casablanca 5
Chennai 5
Council Bluffs 5
Guarulhos 5
Jinan 5
London 5
Mountain View 5
Quảng Ngãi 5
Salto 5
Baghdad 4
Brooklyn 4
Buffalo 4
Can Tho 4
Cercola 4
Chicago 4
Curitiba 4
Guangzhou 4
Hyderabad 4
Jakarta 4
Marcianise 4
Montreal 4
Nanchang 4
Phoenix 4
Phú Nhuận 4
Prague 4
Quito 4
San Giorgio A Cremano 4
Santa Maria 4
Seattle 4
São José dos Pinhais 4
Woodbridge 4
Atibaia 3
Baku 3
Totale 4.596
Salva come PNG Salva come JPEG
Nome #
12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate 173
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 163
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 157
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 154
Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence 153
Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis 152
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis 151
Preliminary results of the FASM study, an on-going italian active pharmacovigilance project 151
Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 148
Is the pathology of posterior cortical atrophy clinically predictable? 147
Apparently isolated CNS involvement in Erdheim-Chester disease: Case report 143
Diagnostic contribution of magnetic resonance imaging in an atypical presentation of motor neuron disease 141
Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study 141
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 140
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 136
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 135
Cd19 cell count at baseline predicts b cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab 135
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis 134
BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab 134
Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study 134
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 133
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study. 132
Clinical activity after fingolimod cessation: disease reactivation or rebound? 132
Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families 131
A real-world study of alemtuzumab in a cohort of Italian patients 128
Disability assessment using Google Maps 127
Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis 126
Correction to: Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 126
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting 124
Signs and symptoms of COVID-19 in patients with multiple sclerosis 121
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 121
Systematic Review on the Role of Lobar Cerebral Microbleeds in Cognition 121
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 120
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 115
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 115
Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome 114
Adiponectin Alleviates Cell Injury due to Cerebrospinal Fluid from Multiple Sclerosis Patients by Inhibiting Oxidative Stress and Proinflammatory Response 114
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 113
Whole-brain propagation delays in multiple sclerosis, a combined tractography - magnetoencephalography study 112
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis 111
Migraine as possible red flag of PFO presence in suspected demyelinating disease 111
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 110
Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis 109
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study 106
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 104
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 103
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience 103
Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis 99
Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study 97
Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity 96
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 95
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 95
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 95
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 93
Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series 93
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy 92
Exploring Circulating Long Non-Coding RNAs in Mild Cognitive Impairment Patients' Blood 92
Nociplastic Pain in Multiple Sclerosis Spasticity: Dermatomal Evaluation, Treatment with Intradermal Saline Injection and Outcomes Assessed by 3D Gait Analysis: Review and a Case Report 92
Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8 + T-Cell Proliferation in Patients With Multiple Sclerosis 86
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 86
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 86
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 85
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 84
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop) 83
Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery. 82
Impact of Lifestyle Interventions on Multiple Sclerosis: Focus on Adipose Tissue 81
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 81
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab 80
Integrated cognitive and neuromotor rehabilitation in multiple sclerosis: A pragmatic study 79
Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis 77
Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) 75
Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study 75
Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis 74
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis 73
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 70
Ocrelizumab in a case of refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with antibodies anti Rituximab 70
MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis 68
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study 67
Italian Alemtuzumab Study Group. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. 67
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study 65
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study 63
Identifying Cladribine prescription pattern in MS: an Italian multicentre study 62
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study 62
Theory of mind in multiple sclerosis: Three-month follow-up effects after double-blind tDCS and video-training, a pilot study 21
Double-negative NMOSD: from case report to a proposed diagnostic and therapeutic algorithm 15
Totale 9.060
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.572
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.572
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202165 0 0 0 0 0 0 0 0 0 21 33 11
2021/2022422 13 38 3 12 99 7 10 8 30 50 25 127
2022/2023701 72 18 9 45 79 42 0 35 353 6 23 19
2023/2024376 23 11 22 21 107 41 33 5 8 3 24 78
2024/20251.432 2 22 8 47 210 194 150 125 228 208 136 102
2025/20265.628 193 291 356 281 498 3.095 346 258 193 117 0 0
Totale 9.060